Zhejiang Beta Pharma Inc.
Records under this name other than patents Zhejiang Beta Pharma Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 6 of 6 · Back to Zhejiang Beta Pharma Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,951,959 | Glucagon-Like PEPTIDE-1 Analogues and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 9,409,900 | Compound for increasing kinase active and application thereof Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,742,138 | Compounds as hypoxia mimetics, and compositions and uses thereof Formerly held Lapsed on the fee record Ended Jun 3, 2026 · USPTO record | Lapsed on the fee record | Ended Jun 3, 2026 | USPTO record |
| US 9,487,570 | Glucagon like peptide analogs, composition, and method of use Formerly held Lapsed on the fee record Ended Nov 8, 2024 · USPTO record | Lapsed on the fee record | Ended Nov 8, 2024 | USPTO record |
| US 9,242,991 | Substituted fused heterocycles as c-Met tyrosine kinase inhibitors Formerly held Lapsed on the fee record Ended Jan 26, 2024 · USPTO record | Lapsed on the fee record | Ended Jan 26, 2024 | USPTO record |
| US 8,822,482 | Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof Formerly held Lapsed on the fee record Ended Sep 2, 2022 · USPTO record | Lapsed on the fee record | Ended Sep 2, 2022 | USPTO record |